Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
Open Access
- 1 January 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (1), 182-188
- https://doi.org/10.1161/01.atv.0000195790.24531.4f
Abstract
Objective— The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn). Methods and Results— Sixty nondiabetic adults with low HDL-C and MetSyn were randomized to PIO or matching placebo for 12 weeks. PIO increased HDL-C by 15% and 14% at 6 and 12 weeks, respectively, compared with placebo ( P r =0.34; P =0.01) but not to changes in insulin resistance. PIO did not affect serum triglycerides or low-density lipoprotein (LDL) cholesterol concentrations but reduced the number of small LDL particles by 18% ( P P P =0.02) while increasing mean serum levels of adiponectin by 111% ( P Conclusions— In nondiabetic patients with low HDL-C and MetSyn, PIO significantly raised HDL-C and favorably affected lipoprotein particle size, markers of inflammation, and adipokines without changes in triglycerides, LDL-C, or weight. These results suggest that PIO has direct effects on HDL, which may contribute to its antiatherogenic effects.Keywords
This publication has 32 references indexed in Scilit:
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- The Metabolic Syndrome: Time for a Critical AppraisalDiabetes Care, 2005
- A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk FactorsArchives of Internal Medicine, 2004
- ThiazolidinedionesNew England Journal of Medicine, 2004
- The triglyceride–high-density lipoprotein axis: An important target of therapy?American Heart Journal, 2004
- Clinical Management of Metabolic SyndromeCirculation, 2004
- Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic EffectDiabetes Care, 2003
- Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled StudyJournal of Clinical Endocrinology & Metabolism, 2002
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002